In order to address these concerns, we propose the

use of peripheral monocytes as NGF delivery vehicles Dinaciclib solubility dmso to the AD brain. We and others have shown that Aβ deposits can stimulate monocyte recruitment and infiltration into the brain (Fiala et al., 1998, Giri et al., 2000 and Humpel, 2008). Furthermore, recent studies have shown that bone marrow-derived or blood-derived monocytic cells are recruited to the diseased AD brain and play an important role in the clearance of Aβ deposits and plaques (El Khoury et al., 2007, Gate et al., 2010 and Lebson et al., 2010). This selective transmigration to amyloid plaques confers a gross advantage for the use of these cells as therapeutic delivery vehicles to the AD brain (Malm et al., 2010 and Schwartz and Shechter, 2010). We hypothesize that following BBB insult (e.g. activation or breakdown) or stimuli

from disease-associated lesion sites (i.e. Aβ plaque), monocytes can transmigrate across the BBB and enter the diseased AD brain (Fig. 5). Monocytes are then attracted to the lesion site by a chemotactic gradient (e.g. monocyte chemotactic Pim inhibitor protein-1 (MCP-1/CCL2)) where they can secrete NGF to support the survival of degenerating cholinergic neurons as well as to reduce amyloid tetracosactide burden by differentiating into macrophages and phagocytosing Aβ (Fig. 5). Although a number of recent

studies have reported on the therapeutic potential of monocytes in AD (Lebson et al., 2010), the role of these cells in contributing to further inflammatory activity and disease aggrevation should still be considered. Their response to neurodegeneration can be beneficial, but ultimately become detrimental once dysregulated and persistent (Shechter and Schwartz, 2013). Other hurdles will include generating large populations of healthy functioning monocytes since these cells are short-lived, exhibit limited numbers in vivo, and are ineffective at Aβ phagocytosis in Alzheimer’s patients (Fiala et al., 2005). In the rat brain, physiological levels of NGF have been reported at 1.01 ng/g tissue and 0.2 ng/g tissue in the hippocampus and cortex, respectively (Whittemore et al., 1986). In mice, reducing NGF brain levels from 13–17 ng/mg in wildtype animals to 6 ng/mg in transgenic anti-NGF animals results in AD-like neurodegeneration (Capsoni et al., 2010). The mechanisms of NGF secretion has been studied extensively in hippocampal neurons and a previous investigation has also shown that monocytes can produce, store, and release NGF (Rost et al., 2005). However, the cellular pathway involved in its release has not been fully characterized.